Gastaldelli et al. [22] conducted a sub-study of the SURPASS-3 trial that included 296 participants with T2D randomized to receive TZP (5, 10, 15 mg) once a week or titrated insulin degludec once per day, with a follow-up period that lasted for 52 weeks. The gene discussed is INS; the disease is type 2 diabetes mellitus.